Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine for Prevention of Depression in Head and Neck Cancer
NCT05724849Phase 2Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of venlafaxine in major depressive disorder (MDD), sponsored by Vanderbilt University Medical Center. Planned start Aug 2023; status: withdrawn.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05724849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724849.